This fact sheet describes the model employed by the Meningitis Vaccine Project to develop a safe, affordable, and long-lasting vaccine with the potential to end Group A meningococcal epidemics in Africa, as well as the contributions of many key partners who made the development of MenAfriVac™ such a success story.
Corporate author(s): PATH
Publication date: September 2011
1,456 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA